This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


  • 00
  • 00
  • 00
  • 00
Delivered as a Hybrid Event from December 12 - 16, 2021
Live In-Person Experience Delivered December 12 - 16 2021Marriott Marquis San Diego

Andreas Plückthun, PhD
Professor and Director, Department of Biochemistry at University of Zurich


Andreas Plückthun, Ph.D., is a Professor of Biochemistry at the University of Zurich, Switzerland. His research on protein engineering has included pioneering work on antibody engineering, the development of ribosome display, new scaffolds (the DARPin technology and Armadillo Repeat Proteins), engineering of stable G-protein coupled receptors towards high stability, and most recently a new retargeting platform for gene therapy. He is member of the German Academy of Science (Leopoldina) and recipient of many international awards. The Protein Society honored him for “pioneering contributions to protein engineering”.

He is co-founder of four biotech companies emerging from his lab, Morphosys (therapeutic antibodies), Molecular Partners (therapeutic DARPins), G7(divested to Heptares/Sosei) (GPCRs) and Vector BioPharma (Adenoviral gene delivery). Trained as chemist in Heidelberg, he received his PhD at UC San Diego, was Postdoc at Harvard, group leader at the Max-Planck-Institute in Martinsried, and then Full Professor in Zurich. His work has been published in over 475 papers, which have been cited over 50,000 times. He is an inventor on more than 25 patent families.

Agenda Sessions

  • The SHREAD Platform: SHielded, REtargeted ADenovirus for the Paracrine Delivery of Therapeutics